The pilot study investigated the effects of vitamin K supplementation versus vitamin K-rich diet in subjects on hemodialysis.
Photo © Shutterstock.com/photographyfirm
A recent pilot study1 investigated the effects of vitamin K supplementation versus vitamin K-rich diet in subjects on hemodialysis. People on hemodialysis are recommended to restrict potassium intake which can lead to a reduction in vitamin K-rich foods. This can ultimately result in vitamin K deficiency which is indicated by high levels of plasma dephosphorylated undercarboxylated matrix Gla protein (dp-ucMGP) and undercarboxylated osteocalcin (ucOC). This is because vitamin K activates osteocalcin (OC) involved in bone mineralization and matrix Gla protein (MGP), an important inhibitor of vascular calcification.
The prospective randomized crossover intervention trial had two arms: six weeks of 360 μg menaquinone-7 (MK-7) tablets per day and six weeks of a vitamin K-rich diet with a three-week washout period between arms. Ten patients on hemodialysis participated in the study. Primary outcome measures were changes in dp-ucMGP and uOC. Results showed that subjects taking the MK-7 supplement experienced significant decreases in dp-ucMGP and uOC compared to vitamin K-rich diet, which did not change levels of dp-ucMGP and uOC.
“This randomized, crossover study may have been small, but the findings suggest that diet alone is not enough to correct vitamin K levels in individuals with chronic kidney disease,” said Ditte Hansen, one of the study’s author, associate professor and specialist in Nephrology at the University of Copenhagen, in a press release. “The pilot study provides promising insights for future developments in the vitamin K space, and suggests that for those who are susceptible to inadequate levels of vitamin K, supplementation may be of importance.”
“While we generally advise a healthy diet first and foremost, diet alone may not be enough to help individuals who are susceptible to vitamin K deficiency achieve a healthy vitamin K status,” added Lena Leder, manager science and content at Kappa Bioscience, which supplied the researchers with the MK-7 supplement, K2Vital Delta. “We believe this pilot study highlights the potential of addressing the growing global vitamin K gap through supplementation and we’re excited that the participants of this study remarked that they found it easier to take tablets rather than altering their diet.”
Reference
Lentz, M.A.; Vahlgren, J.; Hansen, D.; Plebani, M.; Fusaro, M.; Rasmussen, L.M.; et al. Treatment of Vitamin K Deficiency in Hemodialysis Patients – A Pilot Study Comparing Menaquinone-7 Tablets and a Vitamin K Rich Diet. Int J Nephrol Renovasc Dis. 2022, 15: 267-276. DOI: 10.2147/IJNRD.S365912
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.